Short Term Rating on Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals (ACHN) : 7 analysts are covering Achillion Pharmaceuticals (ACHN) and their average rating on the stock is 2.14, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Achillion Pharmaceuticals (ACHN) : 7 Wall Street analysts covering Achillion Pharmaceuticals (ACHN) believe that the average level the stock could reach for the short term is $10. The maximum price target given is $16 and the minimum target for short term is around $7, hence the standard deviation is calculated at $3.37.

For the current week, the company shares have a recommendation consensus of Buy.


Achillion Pharmaceuticals (NASDAQ:ACHN): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.30 and $9.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.24, notching a gain of 0.33% for the day. The total traded volume was 1,348,202 . The stock had closed at $9.21 on the previous day.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *